Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
Hematological Oncology · 2026
DOI: 10.1002/hon.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Cuicui Lyu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Leukemia, Myeloid, Acute. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Tianjin Municipal Health Committee, Tianjin Key Clinical Specialty Construction Project, Tianjin Key Medical Discipline Construction Project.
Abstract (Originalsprache)
Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure. In our previous study, maintenance therapy with a combination of venetoclax and decitabine has shown potential in reducing relapse rates; however, its efficacy and safety, particularly in relation to drug concentration levels, are not yet fully elucidated. This study aimed to evaluate the influence of venetoclax blood concentrations on the efficacy and toxicity of venetoclax plus decitabine as maintenance therapy in high‐risk AML/MDS patients after allo‐HSCT. We retrospectively analyzed clinical data from 58 high‐risk AML/MDS patients who received this maintenance regimen at our center between April 2018 and June 2023, with a focus on the association between venetoclax blood levels, treatment response, and adverse effects. The results demonstrated that the venetoclax–decitabine maintenance regimen was effective and generally well‐tolerated, improving remission rates without significantly increasing intolerable toxicities or the risk of graft‐versus‐host disease (GVHD). Notably, substantial interindividual variability in venetoclax blood concentrations was observed. Patients with concentrations maintained within the range of 2605–4060 ng/mL achieved superior outcomes and higher safety profiles. In conclusion, this study provides key evidence for establishing a target concentration window for venetoclax, highlighting the importance of therapeutic drug monitoring in guiding post‐transplant maintenance therapy for high‐risk AML/MDS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tianjin First Central Hospital, Tianjin Thrombosis and Hemostasis Institute, Tianjin, China.
- Department of Oncology, Xinzhou People's Hospital, Xinzhou, Shanxi, China.
ORCID-Profile: Cuicui Lyu, Mingfeng Zhao
Förderung
- Science and Technology Project of Tianjin Municipal Health Committee
- Tianjin Key Clinical Specialty Construction Project
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Lyu, C., Xie, T., Pu, Y., Luan, X., Xiao, X., Zhao, M., & Lyu, H. (2026). Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Hematological Oncology. https://doi.org/10.1002/hon.70237
Vancouver
Lyu C, Xie T, Pu Y, Luan X, Xiao X, Zhao M, et al. Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. Hematological Oncology. 2026. doi:10.1002/hon.70237
BibTeX
@article{Lyu2026,
author = {Lyu, Cuicui and Xie, Tianle and Pu, Yedi and Luan, Xianshuang and Xiao, Xia and Zhao, Mingfeng and Lyu, Hairong},
title = {Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70237}
}
EUVIMED